Products from BPS Bioscience require a minimum order value above 400€
Encompassing Amino Acids: 2-451 (end)
Applications: Useful for the study of enzyme kinetics, screening inhibitors, and selectivity profiling.
Assay Conditions: Enzyme reaction was conducted in a buffer (25 µl) containing 40 mM Tris-HCl (pH 7.5), 20 mM MgCl2, 100 µM ATP, 0.2 mg/ml poly-(Glu, Tyr), and BRK for 40 min at 30°C. ATP reduction is detected using ADP-Glo™ Kinase Assay Platform (Promega Corporation, Madison, WI).
Background: BRK is a member of the non-receptor tyrosine kinases (PTKs) that contains an amino terminal SH3 and SH2 domain as well as the catalytic domain (1). BRK expression is low or undetectable in normal mammary tissue and benign lesions. However, approximately two-thirds of breast tumors express appreciable levels, and 27% of tumors over express BRK by fivefold or more (2).
Description: Human BRK, also known as PTK6 (GenBank Accession No. NM_005975), 2-451 (end), with N-terminal GST-tag, MW=80 kDa, expressed in Sf9 insect cells via a baculovirus expression system.
Format: Aqueous buffer solution
Formulation: 50 mM Tris-HCl, pH 7.5, 150 mM NaCl, 0.1 mM EDTA, 0.1 mM EGTA, 0.25 mM DTT, 0.1 mM PMSF, and 25% glycerol.
Genbank: NM_005975
Host Cell Line: Sf9 cells
Storage Stability: At least 6 months at -80°C.
Tags: N-terminal GST-tag
Uniprot: Q13882
Warnings: Avoid freeze/thaw cycles.
Biosafety Level: Not applicable (BSL-1)
References: 1. Mitchell, PJ. et al. Oncogene. 1994 Aug,9(8):2383-90.
2. Mitchell, PJ. et al. Oncogene. 1997 Sep 18,15(12):1497-502. Erratum in: Oncogene 1998 Jul 9,17(1):129.
English
Deutsch
